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In recent years, the emergence of antibiotic resistant pathogens made increas-
ingly difficult to establish appropriate empiric antimicrobial therapy protocols for
acute diabetic foot infection (DFI) treatment. Early recognition of the population
at-risk for multidrug-resistant (MDR) bacterial infection is of paramount impor-
tance in order to decrease large-spectrum antibiotic overuse. This study used ret-
rospective cohort study in a multidisciplinary tertiary diabetic foot unit. Patients
with severe DFI were included and divided according to their infection resistance
profile (susceptible vs MDR bacteria). Data regarding their comorbidities and
length of hospital stay were collected. The primary endpoint was to determine
the risk factors for MDR infections and to evaluate if these were associated with
an increased length of stay (LOS). A total of 112 microbial isolates were included.
Predominance of Gram-positive bacteria was observed and 22.3% of isolated bac-
teria were MDR. Previous hospitalisation was associated with a higher likelihood
of MDR infection. MDR bacterial infection was also associated with an increased
LOS (P = .0296). Our study showed a high incidence of MDR bacteria in patients
with a DFI, especially in those who had a recent hospitalisation. MDR infections
were associated with a prolonged LOS and represent a global public health issue
for which emergent measures are needed.
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1 | INTRODUCTION
Diabetic foot infection (DFI) is the most common cause
of nontraumatic amputation, hospitalisation, and reduc-
tion of quality of life in people with diabetes.1
Most moderate and severe DFIs require systemic anti-
biotic therapy. Initial drug choice is usually empirical and
based on the available clinical and epidemiologic data,2
showing the importance of local population studies.
In recent years, the emergence of antibiotic resistant
pathogens made increasingly difficult to select appropri-
ate empirical antibiotic coverage for DFI treatment.3
Based on our local findings, Neves et al4 suggested
piperacillin/tazobactam as the best first-line empirical
antibiotic option to treat moderate-to-severe DFI in our
DF-referral inpatient centre, with an additional
Methicillin-resistant Staphylococcus aureus (MRSA) cov-
erage in high-risk patients.
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However, considering the dynamic environment of
the microbiological flora in DFI, continuous monitoring
of the bacterial prevalence in each diabetic foot centre is
required. As such, this study aimed to analyse the micro-
biological profile of patients admitted to our diabetic foot
centre during the entire year of 2018. Our purpose was
also to identify the risk factors for the development of a
multidrug-resistant (MDR) infection and to determine if
this type of infection was associated with an increase
length of stay (LOS).
2 | METHODS
A retrospective cohort study in a multidisciplinary ter-
tiary diabetic foot unit was conducted. The electronic
medical records of all patients hospitalised during a
1-year period (2018) were retrieved and analysed for rele-
vant epidemiological and clinical data.
The presence of an infected foot ulcer, localised
below the malleolar process of a patient with diabetes
mellitus, was the main inclusion criteria. DFIs are
defined clinically (and not microbiologically) by the
presence of at least two classic symptoms or signs of
inflammation (erythema, warmth, tenderness, pain, or
induration) or purulent exudate.5 The assessment of
infection severity was based on PEDIS scale (perfusion,
extent, depth, infection, sensation), developed by the
International Working Group on the Diabetic Foot.5
Patients with moderate-to-severe disease (PEDIS grade
3 or 4) were included.
The first microbiological sample of all included
patients was analysed. Superficial swabbed samples were
collected by a trained physician after ulcer rinsing with
saline water and gentle debridement of superficial debris,
to avoid commensal flora isolates. In severe cases where
emergent debridement was performed, deep incisional
biopsies were also included in our study.
Standard processing methods for culture and antibiotic
susceptibility test were used by our microbiology labora-
tory department. The anaerobic culture was not performed
due to our lack of standard procedures for handling anaer-
obic samples. “Polymicrobial” cultures or cultures without
isolation of a specific microorganism were excluded from
the study. Isolates and respective in vitro antibiotic suscep-
tibility and resistance profile were recorded. Patients were
then divided into two groups, based on the presence
(or absence) of an MDR infection.
The definition of MDR infection was based on inter-
national standards, published in 2011 by the European
Centre for Disease Prevention and Control and the
Centers for Disease Control and Prevention joint
initiative.6
Statistical analysis for MDR risk factors assessment
was performed using Pearson's chi-square test. “Recent
antibiotherapy” was defined by any registered antibiotic
prescription during the last 6 months. “Hospitalisation
during last year” included all the recorded inpatient
admissions and not only those related to the current dia-
betic foot ulcer. A one-sided t test was performed in order
to access if MDR bacteria were associated with an
increased LOS. A statistical significance of 0.05 with a
confidence level of 95% was used. All analyses were per-
formed with STATA 15, College Station, Texas:
StataCorp.
3 | RESULTS
We studied 103 hospitalisation episodes from 96 patients.
Seven patients were readmitted to our centre during the
study period and each admission was analysed separately
as a new case. Most patients were male (71.2%) and the
mean age was 67.9 (40-90) years.
The first microbiological sample of every patient was
analysed. Contaminated samples (n = 12), negative
microbial results (n = 5), and samples collected after
antibiotherapy initiation (n = 3) were excluded. Thirty
samples had more than one isolate.
A total of 112 bacteria isolates were included in our
study (Table 1). A Gram-positive bacteria predominance
was observed (58.1% of microbial isolates; 1.38/1 Gram-
positive/Gram-negative ratio). S. aureus (SA) was the
most common Gram-positive bacteria (n = 34), followed
by Streptococcus spp (n = 17) and Enterococcus spp
(n = 14). Gram-negative isolates included Pseudomonas
spp (n = 12), Enterobacter spp. (n = 8), and Klebsiella
spp. (n = 8).
Key Messages
• multidrug-resistant (MDR) infections represent
a global public health issue and they are pre-
sent highly in diabetic foot infections
• the risk factors for these infections should be
well known in order to properly address
patients with a high-risk profile
• we conducted a retrospective cohort study
demonstrating that MDR infections were more
common in patients with a recent
hospitalisation and that they were associated
with an increased length of stay
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Nearly a quarter (22.3%; n = 25) of the isolated patho-
gens were MDRs. MRSA (23.5% of all the SA isolates)
was the most frequent MDR bacteria (n = 8), rep-
resenting 32% of total MDRs. Klebsiella pneumoniae
(n = 4; 16% of MDRs), Pseudomonas aeruginosa (n = 4;
16%), and Escherichia coli (n = 3; 12%) were other fre-
quent MDRs.
We analysed several risk factors and associated com-
orbidities (Table 2), namely recent antibiotherapy;
hospitalisation during last year; peripheral artery disease;
chronic kidney disease; retinopathy; and arterial
hypertension.
Patients with a hospitalisation during the last year
had a higher likelihood of MDR infection (P = .03). None
of the other proposed risk factors were considered to be
statistically significant.
The mean LOS in patients infected by an MDR bacte-
ria was 79.8 days and in non-MDR patients was 57.6 days
(Figure 1). Using a one-sided t test, patients with an
MDR infection had a prolonged LOS (P = .0296). Exclud-
ing MRSA infections (covered by a different empirical
antibiotic scheme), the other MDR bacteria (n = 17)
showed a 64.7% resistance to the proposed empirical
antibiotherapy regimen with piperacillin-tazobactam. In
the non-MDR group (excluding SA infections; n = 62),
the piperacillin-tazobactam resistance was 6.4% (n = 4).
The overall resistance for piperacillin-tazobactam in non-
SA infections (n = 79) was 26.5% (n = 21). Ertapenem
resistance was 12% (n = 3) in the MDR group (excluding
MRSA). Overall resistance to ertapenem was 36.7% in the
non-SA group (n = 29).
4 | DISCUSSION
DF infectious process causes a vicious cycle of extensive
decompensation in glucose metabolism, as hyperglyce-
mia further increases the severity of the infection itself.7
As such, proper antibiotic coverage is a key element in
early stabilisation of these patients and should be based
on known potential etiologic agents.
In Portugal, few studies have been performed to char-
acterise the local causative pathogens of DFIs. An appar-
ent Gram-positive predominance (especially of
Staphylococcus) has been initially suggested4,8-10 but
some authors had recently described a shift towards
Gram-negative isolates, possibly in relation with the ris-
ing prevalence of neuroischemic infected ulcers.11 Our
results do not corroborate these latest findings but we
acknowledge that they should be properly confirmed by
further larger studies.
Regarding MDR infections, a high incidence has been
ubiquitously described4,8-11 and our study also highlights
that these infections correlate with an increased LOS.
Despite controversy regarding the association of MDR
infections with a worse outcome in DFIs,12-14 our data
are a surrogate marker for a poor overall prognosis.
Some authors suggested that previous
hospitalisation,14,15 long-standing diabetes,16 recent
antibiotherapy,15 retinopathy,17 ulcer size,15,16 and the pres-
ence of osteomyelitis14,15 were associated with an increased
risk of an MDR infection. In our study, we were able to
show that hospitalisation during the previous year is a sta-
tistically significant risk factor for the occurrence of DFI by
MDR bacteria. However, given our limited sample and the
retrospective nature of our study, we were unable to find
any other factors associated with a statistically significant
increased risk for an MDR infection.
The absence of well-defined, evidence-based policy of
broad spectrum antibiotherapy has led to overuse and to
a strikingly increase in the number of MDR bacteria.18
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Our study shows an alarming resistance of these agents
to a recently optimised empirical antibiotherapy regi-
men, suggesting that we are running off of proper anti-
biotics for DFI.18-21 Currently in our unit we are facing
a huge dilemma: should we use piperacillin-tazobactam,
prioritising a better overall coverage but knowing that
we are delaying proper care for the severe MDR infec-
tions, linked to poorer outcomes? Or must we be
focused on these MDR agents, favouring ertapenem
usage and acknowledging that we are allowing more
non-MDR to be mistreated?
In our view, the solution relies on multiple empiric
antibiotic regimens that are guided by the patient risk
factors for MDR infections. As such, we believe that
future studies should be focused on the development of a
reliable risk stratification tool, allowing proper antibiotic
selection for both high and low-risk patients.
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